Financial Avengers’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Financial Avengers’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1	Closed	-$187	–	158
2024 Q4	$187	Hold	1	–	–	﹤0.01%	159
2024 Q3	$78	Hold	1	–	–	﹤0.01%	175
2024 Q2	$75	Hold	1	–	–	﹤0.01%	154
2024 Q1	$109	Hold	1	–	–	﹤0.01%	148
2023 Q4	$105	Hold	1	–	–	﹤0.01%	175
2023 Q3	$112	Hold	1	–	–	﹤0.01%	174
2023 Q2	$151	Hold	1	–	–	﹤0.01%	151
2023 Q1	$156	Hold	1	–	–	﹤0.01%	167
2022 Q4	$64	Hold	1	–	–	﹤0.01%	180
2022 Q3	$0	Hold	1	–	–	﹤0.01%	148
2022 Q2	$0	Hold	1	–	–	﹤0.01%	154
2022 Q1	$1K	Hold	1	–	–	﹤0.01%	143
2021 Q4	$1K	Hold	1	–	–	﹤0.01%	153
2021 Q3	$9K	Hold	1	–	–	0.01%	120
2021 Q2	$5K	Hold	1	–	–	﹤0.01%	139
2021 Q1	$4K	Hold	1	–	–	﹤0.01%	143
2020 Q4	$3K	Buy	+1	New	+$8.86K	﹤0.01%	149

Other funds holding IRLA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Financial Avengers's IRLA Position: Q1 2025 in Review

Financial Avengers sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q1 2025, closing a stake of 1 share — an estimated $187 sold.

Financial Avengers first reported a position in IRLA in Q4 2020 and held it in 17 quarters. The position peaked at $9K in Q3 2021. 32 funds tracked by Wall St. Rank hold IRLA as of Q1 2025.

Financial Avengers reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Financial Avengers sold 1 IRulya Therapeutics Inc. Common Stock share in Q1 2025, an estimated $187.
Financial Avengers first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2020 and held it in 17 quarters.
Financial Avengers's IRulya Therapeutics Inc. Common Stock position peaked at $9K in Q3 2021.
32 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q1 2025.

Based on Financial Avengers's 13F filing for Q1 2025, filed 15 May 2025.